At the news
? NEUTRALIMPACT 3/10 8-K filed Jun 26, 2026 at 16:01 ET
SCYNEXIS filed an 8-K reporting shareholder approval to increase authorized common stock from 18.75M to 60M shares (post reverse-split), enabling the exercise of outstanding warrants held by selling stockholders. The filing also confirms the effectiveness of a previously filed S-3 registration statement covering up to 10.875M post-split shares for resale. This is a procedural step in the capital restructuring announced in March 2026, with no new financial disclosures or immediate fundraising.
- Authorized common stock increased from 18,750,000 to 60,000,000 shares (post-1-for-8 reverse split effective May 29, 2026).
- Shareholders approved the amendment at the June 25, 2026 Annual Meeting.
- Registration statement on Form S-3 (effective May 8, 2026) registers up to 10,875,000 post-split shares for resale by selling stockholders.
- Warrants (pre-funded and common) became exercisable upon the effectiveness of the authorized share increase on June 26, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access